<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049919</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IDE 13996</org_study_id>
    <secondary_id>BBIO.CR.CT002</secondary_id>
    <nct_id>NCT01049919</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)</brief_title>
  <acronym>MOBILE</acronym>
  <official_title>MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects With Severe Peripheral Arterial Disease (PAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA)&#xD;
      to prevent or delay major amputation and/or death in subjects with critical limb ischemia&#xD;
      (CLI) due to severe peripheral arterial disease (PAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo controlled, multicenter trial&#xD;
      intended for subjects with critical limb ischemia (CLI) that are unsuitable for&#xD;
      revascularization. The investigational treatment utilizes autologous concentrated bone marrow&#xD;
      aspirate (cBMA) at the point of care. The bone marrow aspirate is obtained from the subject's&#xD;
      hip, concentrated with a bone marrow concentration device, and delivered intramuscularly to&#xD;
      the affected limb. Subjects meeting the inclusion/exclusion criteria will be randomized to&#xD;
      receive either the investigational treatment (cBMA) or a placebo control (sham treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary endpoint not met, remaining long-term follow-up not needed.&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Major Amputation or Death</measure>
    <time_frame>52 weeks</time_frame>
    <description>Occurrence of major amputation (above the ankle joint) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) - Pain</measure>
    <time_frame>52 weeks</time_frame>
    <description>Pain reported at the 52-week follow-up visit as assessed on the visual analog scale (VAS). Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; The distance from the beginning of the line is measured and reported in centimeters (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-Minute Walk Test</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measurement (in meters) of the total distance a participant is able to walk in 6 minutes. Since ability to walk is related to the condition of the affected limb, this measure is tied to limb pain and function. If a participant had multiple limbs included in the study, each limb was evaluated separately. Only one limb could be included in the study at a time.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of Major Amputation or Death</measure>
    <time_frame>5 years</time_frame>
    <description>Occurrence of major amputation (above the ankle joint) or death for all participants through final follow-up.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Concentrated bone marrow aspirate (cBMA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control (sham)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone marrow concentration device</intervention_name>
    <description>Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
    <arm_group_label>Concentrated bone marrow aspirate (cBMA)</arm_group_label>
    <other_name>Bone marrow concentrate</other_name>
    <other_name>Bone marrow mononuclear cells</other_name>
    <other_name>MarrowStim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo procedure (sham)</intervention_name>
    <description>Sham bone marrow aspiration, sham delivery to affected limb</description>
    <arm_group_label>Placebo control (sham)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial&#xD;
             disease&#xD;
&#xD;
          -  Unsuitable for revascularization&#xD;
&#xD;
          -  Minor tissue loss (Rutherford Category 5) or ischemic rest pain (Rutherford Category&#xD;
             4) with ABI ≤ 0.6, or TBI ≤ 0.4, or TcPO2 ≤ 50 mm Hg&#xD;
&#xD;
          -  Competent to give consent&#xD;
&#xD;
          -  No current malignancy or history of previous malignancy within the last five years,&#xD;
             with the exception of adequately treated non-melanoma skin cancer (evidence of&#xD;
             standard preventative cancer screenings required)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major tissue loss (Rutherford Category 6)&#xD;
&#xD;
          -  Diabetics on oral or insulin therapy with uncontrolled or untreated proliferative&#xD;
             retinopathy (evidence of retinal exam required)&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus with HbA1C &gt; 10% (evidence of HbA1C test required)&#xD;
&#xD;
          -  Uncompensated congestive heart failure (New York Heart Association Class IV) and/or&#xD;
             other conditions that preclude general anesthesia&#xD;
&#xD;
          -  Myocardial infarction or stroke within last 90 days&#xD;
&#xD;
          -  Elevated liver function tests (AST or ALT more than twice normal upper limit)&#xD;
&#xD;
          -  Renal disease (creatinine &gt; 2.5 mg/dl) or chronic hemodialysis&#xD;
&#xD;
          -  White blood cell count &lt; 3,000/µL or &gt; 15,000/µL, platelet count &lt; 100,000/µL, or&#xD;
             hematocrit &lt; 32%&#xD;
&#xD;
          -  Topical growth hormone therapy within last 90 days, or injected growth hormone therapy&#xD;
             within last 180 days&#xD;
&#xD;
          -  Disease of central nervous system and/or other conditions that impair cognitive&#xD;
             function&#xD;
&#xD;
          -  Two or more episodes of pulmonary embolus with a documented DVT in index leg or&#xD;
             history of DVT in index leg without evidence of clot resolution&#xD;
&#xD;
          -  Current infection of index leg&#xD;
&#xD;
          -  Pregnant women (negative urine pregnancy test required)&#xD;
&#xD;
          -  Lower extremity venous disease with pitting edema in index leg&#xD;
&#xD;
          -  Recent history (in the 6 months prior to screening) of bone marrow disease or&#xD;
             treatment with any medication or procedure which adversely affects the bone marrow and&#xD;
             would prohibit transplantation&#xD;
&#xD;
          -  Current osteomyelitis in index leg&#xD;
&#xD;
          -  Existing HIV diagnosis&#xD;
&#xD;
          -  Organ transplant recipients&#xD;
&#xD;
          -  Known terminal disease process with life expectancy less than one year&#xD;
&#xD;
          -  Severe concomitant disease(s) or any additional condition(s) which the investigator&#xD;
             feels constitute(s) criteria for exclusion of a particular subject&#xD;
&#xD;
          -  Major amputation required within 30 days&#xD;
&#xD;
          -  Inclusion in any other clinical study that may affect the outcome of this study&#xD;
&#xD;
          -  Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac&#xD;
             artery and/or common femoral artery of the index leg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Health Care</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska-Western Iowa VA Healthcare System</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College / New York-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011 Jun;53(6):1565-74.e1. doi: 10.1016/j.jvs.2011.01.074. Epub 2011 Apr 22.</citation>
    <PMID>21514773</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <disposition_first_submitted>June 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 23, 2017</disposition_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>CLI</keyword>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Limb Salvage</keyword>
  <keyword>Amputation</keyword>
  <keyword>Leg Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment in the study occurred between June 2010 and June 2015. Until February 2014, participants completing the initial 52-week follow-up period could choose to have their second limb randomized if the participant and limb continued to meet all study inclusion and exclusion criteria. Three (3) limbs were enrolled during this time, resulting in a total of 155 limbs in 152 participants that were included in the final intent-to treat analysis for the primary endpoint.</recruitment_details>
      <pre_assignment_details>Participants that provided informed consent, completed all screening assessments, and met all inclusion and exclusion criteria for the study went on to be randomized and undergo the study procedure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
          <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control (Sham)</title>
          <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="36">One participant is counted in both treatment groups due to one leg being randomized to each group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="19">Incl. 11 participants that received crossover treatment after completing 52 week primary follow up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met study endpoint (major amputation, death)</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received 2nd treatment via compassionate use</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early study termination by sponsor.</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
          <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control (Sham)</title>
          <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Limbs</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean age for all limbs. If a participant had multiple limbs evaluated, his/her age would be included multiple times in the analysis.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="11.9"/>
                    <measurement group_id="B2" value="66.7" spread="12.2"/>
                    <measurement group_id="B3" value="65.0" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Count of race/ethnicity for all limbs. If a participant had multiple limbs evaluated, his/her race/ethnicity would be included multiple times in the analysis.</description>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (non-Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rutherford Score</title>
          <description>The Rutherford score is a classification of severity for peripheral artery disease which ranges from 0 (asymptomatic) to 6 (major tissue loss extending above the transmetatarsal level, functional foot no longer salvageable). The study enrolled participants with Rutherford scores of 4 (ischemic rest pain) and 5 (minor tissue loss, nonhealing ulcer, and/or focal dry gangrene).</description>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rutherford Score = 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford Score = 5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Status</title>
          <description>Describes diabetic status of all limbs. If a participant had multiple limbs evaluated, his/her diabetic status would be included multiple times in the analysis.</description>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diabetes = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diabetes = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Major Amputation or Death</title>
        <description>Occurrence of major amputation (above the ankle joint) or death.</description>
        <time_frame>52 weeks</time_frame>
        <population>All limbs that were randomized to a treatment group were included in the analysis for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
            <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control (Sham)</title>
            <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Major Amputation or Death</title>
          <description>Occurrence of major amputation (above the ankle joint) or death.</description>
          <population>All limbs that were randomized to a treatment group were included in the analysis for the primary endpoint.</population>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) - Pain</title>
        <description>Pain reported at the 52-week follow-up visit as assessed on the visual analog scale (VAS). Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; The distance from the beginning of the line is measured and reported in centimeters (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
        <time_frame>52 weeks</time_frame>
        <population>All limbs that were randomized to a treatment group, did not meet a primary endpoint or otherwise exit from the study, and that had an assessment available at 52 weeks were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
            <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control (Sham)</title>
            <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) - Pain</title>
          <description>Pain reported at the 52-week follow-up visit as assessed on the visual analog scale (VAS). Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; The distance from the beginning of the line is measured and reported in centimeters (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
          <population>All limbs that were randomized to a treatment group, did not meet a primary endpoint or otherwise exit from the study, and that had an assessment available at 52 weeks were included in the analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Limbs</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.462" spread="7.789"/>
                    <measurement group_id="O2" value="5.836" spread="2.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Limbs</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.651" spread="2.964"/>
                    <measurement group_id="O2" value="3.346" spread="3.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>Treatment-by-week p-value is reported.</p_value_desc>
            <method>Repeated measures model</method>
            <method_desc>The statistical analysis model includes treatment group, week, treatment-by-week, and baseline pain measurement.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-Minute Walk Test</title>
        <description>Measurement (in meters) of the total distance a participant is able to walk in 6 minutes. Since ability to walk is related to the condition of the affected limb, this measure is tied to limb pain and function. If a participant had multiple limbs included in the study, each limb was evaluated separately. Only one limb could be included in the study at a time.</description>
        <time_frame>52 weeks</time_frame>
        <population>All limbs that were randomized to a treatment group, did not meet a primary endpoint or otherwise exit from the study, and that had an assessment available at 52 weeks were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
            <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control (Sham)</title>
            <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
          </group>
        </group_list>
        <measure>
          <title>Six-Minute Walk Test</title>
          <description>Measurement (in meters) of the total distance a participant is able to walk in 6 minutes. Since ability to walk is related to the condition of the affected limb, this measure is tied to limb pain and function. If a participant had multiple limbs included in the study, each limb was evaluated separately. Only one limb could be included in the study at a time.</description>
          <population>All limbs that were randomized to a treatment group, did not meet a primary endpoint or otherwise exit from the study, and that had an assessment available at 52 weeks were included in the analysis.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Limbs</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.508" spread="115.157"/>
                    <measurement group_id="O2" value="173.114" spread="130.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Limbs</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.545" spread="170.015"/>
                    <measurement group_id="O2" value="218.352" spread="148.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.714</p_value>
            <p_value_desc>Treatment-by-week p-value is reported.</p_value_desc>
            <method>Repeated measures model</method>
            <method_desc>The statistical analysis model includes treatment group, week, treatment-by-week, and baseline pain measurement.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Occurrence of Major Amputation or Death</title>
        <description>Occurrence of major amputation (above the ankle joint) or death for all participants through final follow-up.</description>
        <time_frame>5 years</time_frame>
        <population>All randomized participants were included in the analysis. Some participants did not re-consent for follow-up after 52 weeks and as such their long-term status is unknown. For the purposes of this analysis, they are counted with those who completed follow-up. Control participants that received crossover therapy with cBMA after 52 weeks are counted with the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
            <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control (Sham)</title>
            <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Major Amputation or Death</title>
          <description>Occurrence of major amputation (above the ankle joint) or death for all participants through final follow-up.</description>
          <population>All randomized participants were included in the analysis. Some participants did not re-consent for follow-up after 52 weeks and as such their long-term status is unknown. For the purposes of this analysis, they are counted with those who completed follow-up. Control participants that received crossover therapy with cBMA after 52 weeks are counted with the control group.</population>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Occurrence of Major Amputation or Death, Excluding Rutherford 5 Diabetic Subjects</title>
        <description>Occurrence of major amputation (above the ankle joint) or death, excluding the subgroup of subjects with Rutherford Category 5 critical limb ischemia and diabetes.&#xD;
The Rutherford score is a classification of severity for peripheral artery disease which ranges from 0 (asymptomatic) to 6 (major tissue loss extending above the transmetatarsal level, functional foot no longer salvageable). The study enrolled participants with Rutherford scores of 4 (ischemic rest pain) and 5 (minor tissue loss, nonhealing ulcer, and/or focal dry gangrene).</description>
        <time_frame>52 weeks</time_frame>
        <population>All limbs for subjects from the following subgroups that were randomized to a treatment group were included in this post-hoc analysis: Rutherford Category 4 and diabetic, Rutherford Category 4 and non-diabetic, Rutherford Category 5 and non-diabetic.</population>
        <group_list>
          <group group_id="O1">
            <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
            <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control (Sham)</title>
            <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Major Amputation or Death, Excluding Rutherford 5 Diabetic Subjects</title>
          <description>Occurrence of major amputation (above the ankle joint) or death, excluding the subgroup of subjects with Rutherford Category 5 critical limb ischemia and diabetes.&#xD;
The Rutherford score is a classification of severity for peripheral artery disease which ranges from 0 (asymptomatic) to 6 (major tissue loss extending above the transmetatarsal level, functional foot no longer salvageable). The study enrolled participants with Rutherford scores of 4 (ischemic rest pain) and 5 (minor tissue loss, nonhealing ulcer, and/or focal dry gangrene).</description>
          <population>All limbs for subjects from the following subgroups that were randomized to a treatment group were included in this post-hoc analysis: Rutherford Category 4 and diabetic, Rutherford Category 4 and non-diabetic, Rutherford Category 5 and non-diabetic.</population>
          <units>Limbs</units>
          <param>Count of Units</param>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring from the start of study treatment up to the 52-week follow-up visit were recorded. Between 52 weeks and 5 years, only major adverse limb events, including those resulting in major amputation, and death were recorded. Serious adverse events are reported through 52 weeks. All-cause mortality is reported through 5 years. Not all participants re-consented to additional follow-up after week 52, so mortality information was only available for those that re-consented.</time_frame>
      <desc>Participants were asked to report adverse events during all follow-up visits, and site staff were to review medical records available between visits to determine if additional events had occurred that were not reported by participants. Although some events were not limb-related, they were recorded and counted for each enrolled limb. If a participant had multiple limbs included in the study, events for each limb were evaluated separately. Only one limb was included in the study at a time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Concentrated Bone Marrow Aspirate (cBMA)</title>
          <description>Bone marrow concentration device: Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control (Sham)</title>
          <description>Placebo procedure (sham): Sham bone marrow aspiration, sham delivery to affected limb</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Red Blood Cell-Related Level</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Asystole Episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cardiac Decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ischemic Bowel</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ileocolic Anastomotic Leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Large Bowel Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>General Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Non-Healing of Toe Amputation Site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Prolonged Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis Related to Antibiotic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infection - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Osteomyelitis - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal Sepsis/Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cellulitis - Arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cellulitis - Bilateral Legs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cellulitis - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infected Abdominal Mesh</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infection - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Osteomyelitis - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fracture - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Weakness - Hand</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Degenerative Disc - Cervical Spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Oversedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Fibroids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Menstruation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gangrene - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Wound - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ulceration - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Wound - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abscess - Buttock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ulceration - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Major Amputation - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Toe Amputation - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bypass Graft - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Amputation of Foot - Contralateral Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Amputation of Toe - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Major Amputation - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Angioplasty - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Angioplasty - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Knee Revision - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemia - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Non-ST-Elevation Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Carotid Blockage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Near Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Superior Mesenteric Artery Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stenosis of Bypass Graft - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Venous Thromboembolism - Contralateral Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Red Blood Cell-Related Level</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Low White Blood Cell-Related Level</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>High White Blood Cell-Related Level</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>High Red Blood Cell-Related Level</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Bilateral Iliac Crests</sub_title>
                <description>Pain from bone marrow aspiration procedure.</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infection - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Edema - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Hip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Numbness - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ulceration - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Erythema - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Wound - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gangrene - Index Leg</sub_title>
                <description>Dry gangrene</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fissure - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pruritis - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bypass Graft - Index Leg</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hillary Overholser</name_or_title>
      <organization>Zimmer Biomet</organization>
      <phone>574-373-2042</phone>
      <email>hillary.overholser@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

